INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 222 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $18,000 | -14.3% | 950 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $21,000 | -8.7% | 950 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $23,000 | -100.0% | 950 | -99.9% | 0.00% | -100.0% |
| Q3 2020 | $49,793,000 | -13.5% | 1,201,000 | 0.0% | 5.86% | -8.4% |
| Q2 2020 | $57,539,000 | -20.9% | 1,201,000 | +4.0% | 6.40% | -31.0% |
| Q1 2020 | $72,718,000 | -31.8% | 1,155,000 | +34.3% | 9.28% | +4.9% |
| Q4 2019 | $106,571,000 | +88.7% | 860,000 | +1.1% | 8.85% | +25.0% |
| Q3 2019 | $56,472,000 | -6.2% | 851,000 | +12.4% | 7.08% | -5.8% |
| Q2 2019 | $60,234,000 | +68.3% | 757,000 | +136.6% | 7.51% | +39.3% |
| Q1 2019 | $35,795,000 | +557.8% | 320,000 | +492.6% | 5.39% | +346.8% |
| Q4 2018 | $5,442,000 | -83.3% | 54,000 | -79.0% | 1.21% | -83.2% |
| Q3 2018 | $32,537,000 | -39.0% | 257,500 | -59.5% | 7.18% | -32.8% |
| Q2 2018 | $53,308,000 | +36.4% | 635,300 | 0.0% | 10.69% | +18.2% |
| Q1 2018 | $39,083,000 | +267.0% | 635,300 | +248.5% | 9.04% | +231.8% |
| Q4 2017 | $10,649,000 | – | 182,300 | – | 2.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |